AbbVie (MEX:ABBV) Notes Receivable: MXN0 Mil (As of Mar. 2026)


MEX:ABBV AbbVie Inc MEX:ABBV
72 GF Score
Price MXN4,411.00
GF Value MXN3,710.37
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Notes Receivable?

AbbVie MEX:ABBV -0.84% 72 Notes Receivable is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:ABBV with a GF Score™ of 72/100 and a GF Value™ of MXN3,710.37 (Modestly Overvalued). The stock has 4 warning signs investors should review.

AbbVie's Notes Receivable for the quarter that ended in Mar. 2026 was MXN0 Mil.

AbbVie Notes Receivable Historical Data

* Premium members only.

The historical data trend for AbbVie's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Notes Receivable Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:ABBV
72GF Score
AbbVie Inc MEX:ABBV
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of MXN0 Mil mean?
AbbVie (MEX:ABBV) has a Notes Receivable of MXN0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on AbbVie and its competitors.
Is AbbVie's Notes Receivable too high?
AbbVie's current Notes Receivable is MXN0 Mil. Overall, AbbVie has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Notes Receivable compare to MRK and JNJ?
AbbVie's Notes Receivable of MXN0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on AbbVie and its competitors. AbbVie's current Notes Receivable is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (MEX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN3,710.37, compared to a current price of MXN4,411.00 — trading 18.9% above its estimated fair value. The current Notes Receivable is MXN0 Mil. AbbVie's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For AbbVie (MEX:ABBV), the current Notes Receivable is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (MEX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of MXN4,411.00 is trading 18.9% above its estimated GF Value™ of MXN3,710.37. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for MEX:ABBV:

  • Notes Receivable: MXN0 Mil
  • GF Value™: MXN3,710.37 vs. price of MXN4,411.00 (18.9% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
72GF Score

Get the complete analysis for MEX:ABBV

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,411.00
Price
MXN3,710.37
GF Value